基于供方视角的我国帕金森病患者直接医疗成本测算

Estimation on Direct Medical Cost of Patients with Parkinson's Disease in China from the Perspective of Suppliers

目的:基于供方视角,探究我国帕金森病患者的直接医疗成本。方法:对我国19个省66家三级医院的102名帕金森病临床专家进行问卷调查,获得帕金森病各进展期患者医疗服务利用的平均单价、频率、占比以及药物的平均剂量、频率等成本数据,计算获得各期患者年平均成本。结果:当前我国帕金森病患者早期(Hoehn-YahrⅠ期和Ⅱ期)、Ⅲ期、Ⅳ期、Ⅴ期的年平均直接医疗成本分别为6721.79元、27982.01元、37324.54元和42326.63元。在各期成本中,药品成本占比较大。结论:我国帕金森病患者医疗成本较高,经济负担较重,应建立与国际一致的规范化管理模式。

Objective Based on the supplier's perspective,this paper explores the direct medical cost of patients with Parkinson's disease in China.Methods A questionnaire survey was conducted among 102 Parkinson's disease clinical experts from 66 tertiary hospitals in 19 provinces.The questionnaire obtain the cost data of patients in each stage progression of Parkinson's disease,mainly including the average unit price,frequency,proportion of medical service utilization,the proportion and average dose of drugs,then calculate the annual average cost of patients in each stage.Results At present,the average annual direct medical costs of patients with Parkinson's disease in early stage(Hoehn-YahrⅠandⅡ),Ⅲ,ⅣandⅤare 6721.79RMB,27982.01RMB,37324.54RMB and 42326.63RMB.Among the costs of each period,the cost of drugs accounts for a relatively large proportion.Conclusion In China,the medical cost of patients with Parkinson's disease is higher and their economic burden is heavy,so an international standardized management model should be established.